<SEC-DOCUMENT>0001140361-21-036636.txt : 20211104
<SEC-HEADER>0001140361-21-036636.hdr.sgml : 20211104
<ACCEPTANCE-DATETIME>20211104213221
ACCESSION NUMBER:		0001140361-21-036636
CONFORMED SUBMISSION TYPE:	3
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20211104
FILED AS OF DATE:		20211104
DATE AS OF CHANGE:		20211104

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			Andersson Claus A.
		CENTRAL INDEX KEY:			0001890710

	FILING VALUES:
		FORM TYPE:		3
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-41008
		FILM NUMBER:		211382022

	MAIL ADDRESS:	
		STREET 1:		1209 ORANGE STREET
		CITY:			WILMINGTON
		STATE:			DE
		ZIP:			19801

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			IO Biotech, Inc.
		CENTRAL INDEX KEY:			0001865494
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				870909276
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	BUSINESS ADDRESS:	
		STREET 1:		OLE MAALOES VEH 3
		CITY:			COPENHAGEN
		STATE:			G7
		ZIP:			2200
		BUSINESS PHONE:		4570702980

	MAIL ADDRESS:	
		STREET 1:		OLE MAALOES VEH 3
		CITY:			COPENHAGEN
		STATE:			G7
		ZIP:			2200
</SEC-HEADER>
<DOCUMENT>
<TYPE>3
<SEQUENCE>1
<FILENAME>form3.xml
<DESCRIPTION>FORM 3
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0206</schemaVersion>

    <documentType>3</documentType>

    <periodOfReport>2021-11-04</periodOfReport>

    <noSecuritiesOwned>0</noSecuritiesOwned>

    <issuer>
        <issuerCik>0001865494</issuerCik>
        <issuerName>IO Biotech, Inc.</issuerName>
        <issuerTradingSymbol>IOBT</issuerTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001890710</rptOwnerCik>
            <rptOwnerName>Andersson Claus A.</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>C/O IO BIOTECH, INC.</rptOwnerStreet1>
            <rptOwnerStreet2>OLE MAALOES VEH 3</rptOwnerStreet2>
            <rptOwnerCity>COPENHAGEN</rptOwnerCity>
            <rptOwnerState>G7</rptOwnerState>
            <rptOwnerZipCode>2200</rptOwnerZipCode>
            <rptOwnerStateDescription>DENMARK</rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>true</isDirector>
        </reportingOwnerRelationship>
    </reportingOwner>

    <derivativeTable>
        <derivativeHolding>
            <securityTitle>
                <value>Series B Preferred Stock</value>
            </securityTitle>
            <conversionOrExercisePrice>
                <footnoteId id="F1"/>
            </conversionOrExercisePrice>
            <exerciseDate>
                <footnoteId id="F1"/>
            </exerciseDate>
            <expirationDate>
                <footnoteId id="F1"/>
            </expirationDate>
            <underlyingSecurity>
                <underlyingSecurityTitle>
                    <value>Common Stock</value>
                </underlyingSecurityTitle>
                <underlyingSecurityShares>
                    <value>1361660</value>
                </underlyingSecurityShares>
            </underlyingSecurity>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>I</value>
                </directOrIndirectOwnership>
                <natureOfOwnership>
                    <value>See footnote</value>
                    <footnoteId id="F3"/>
                </natureOfOwnership>
            </ownershipNature>
        </derivativeHolding>
        <derivativeHolding>
            <securityTitle>
                <value>Series C Preferred Stock</value>
            </securityTitle>
            <conversionOrExercisePrice>
                <footnoteId id="F2"/>
            </conversionOrExercisePrice>
            <exerciseDate>
                <footnoteId id="F2"/>
            </exerciseDate>
            <expirationDate>
                <footnoteId id="F2"/>
            </expirationDate>
            <underlyingSecurity>
                <underlyingSecurityTitle>
                    <value>Common Stock</value>
                </underlyingSecurityTitle>
                <underlyingSecurityShares>
                    <value>354830</value>
                </underlyingSecurityShares>
            </underlyingSecurity>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>I</value>
                </directOrIndirectOwnership>
                <natureOfOwnership>
                    <value>See footnote</value>
                    <footnoteId id="F3"/>
                </natureOfOwnership>
            </ownershipNature>
        </derivativeHolding>
    </derivativeTable>

    <footnotes>
        <footnote id="F1">Upon the closing of the Issuer's initial public offering (&quot;IPO&quot;), each share of Series B Preferred Stock beneficially owned by the reporting person will automatically convert, for no additional consideration, into the number of shares of Common Stock reported in Column 3. These shares of Series B Preferred Stock have no expiration date.</footnote>
        <footnote id="F2">Upon the closing of the Issuer's initial public offering (&quot;IPO&quot;), each share of Series C Preferred Stock beneficially owned by the reporting person will automatically convert, for no additional consideration, into the number of shares of Common Stock reported in Column 3. These shares of Series C Preferred Stock have no expiration date.</footnote>
        <footnote id="F3">Sunstone Life Science Ventures Fund III K/S (&quot;Sunstone Fund III&quot;). Sunstone LSV General Partner III ApS (&quot;Sunstone LSV GP III&quot;) is the general partner of Sunstone Fund III and has voting and dispositive power over all of the shares of held by Sunstone Fund III. The reporting person is a General Partner of Sunstone Life Science Ventures A/S and a member of the executive board of Sunstone LSV GP III, and shares voting and dispositive power with respect to the shares held by Sunstone Fund III.  The reporting person disclaims beneficial ownership of the shares held directly by Sunstone Fund III except to the extent of his pecuniary interest therein.</footnote>
    </footnotes>

    <remarks>Exhibit List: Exhibit 24 - Power of Attorney</remarks>

    <ownerSignature>
        <signatureName>/s/ Brian Burkavage, Attorney-in-Fact for Claus Andersson</signatureName>
        <signatureDate>2021-11-04</signatureDate>
    </ownerSignature>
</ownershipDocument>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-24
<SEQUENCE>2
<FILENAME>andersson.htm
<DESCRIPTION>EXHIBIT 24
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Summit, a Broadridge Company
         Document created using EDGARfilings PROfile 8.0.0.0
         Copyright 1995 - 2021 Broadridge -->
  </head>
<body style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;" bgcolor="#ffffff">
  <div>
    <div style="text-align: center; font-weight: bold;">POWER OF ATTORNEY</div>
    <div>&#160;</div>
    <div style="text-indent: 36pt;">Know all by these presents, that the undersigned hereby makes, constitutes and appoints each of <u>Keith Vendola</u>, <u>Mai-Britt Zocca</u>, and <u>Brian Burkavage</u>, or any of them acting individually, and with
      full power of substitution, the undersigned's true and lawful attorney-in-fact to:</div>
    <div>&#160;</div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z5fff019077944d158ccb5ba2b6aa8b3d" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 27pt;"><br>
          </td>
          <td style="width: 31.5pt; vertical-align: top; align: right; color: #1F1F1F;">(1)</td>
          <td style="width: auto; vertical-align: top;">
            <div style="color: #1F1F1F;">prepare, execute in the undersigned's name and on the undersigned's behalf, and submit to the U.S. Securities and Exchange Commission (the "SEC") a Form ID, including amendments thereto, and any other documents
              necessary or appropriate to obtain codes and passwords enabling the undersigned to make electronic filings with the SEC of reports required by Section 16(a) of the Securities Exchange Act of 1934 or any rule or regulation of the SEC;</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zc65ba30a5aa4455d87e62d938af9b1ac" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 27pt;"><br>
          </td>
          <td style="width: 31.5pt; vertical-align: top; align: right; color: #1F1F1F;">(2)</td>
          <td style="width: auto; vertical-align: top;">
            <div><font style="color: #1F1F1F;">execute for and on behalf of the undersigned, in the undersigned's capacity as an officer and/or director of </font>IO Biotech, Inc., <font style="color: #1F1F1F;">a Delaware corporation (the "Company"),
                Forms 3, 4, and 5, including amendments thereto, in accordance with Section 16(a) of the Securities Exchange Act of 1934 and the rules and regulations thereunder;</font></div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zf587199cc9ca4f1a90e19e65d60c3d18" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 27pt;"><br>
          </td>
          <td style="width: 31.5pt; vertical-align: top; align: right;">(3)</td>
          <td style="width: auto; vertical-align: top;">
            <div style="color: #1F1F1F;">do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Form 3, 4, or 5, complete and execute any amendment or amendments thereto,
              and timely file such form with the SEC and any stock exchange or similar authority; and</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zc5ad1ac53a324ca78a2f4662dac368e4" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 27pt;"><br>
          </td>
          <td style="width: 31.5pt; vertical-align: top; align: right;">(4)</td>
          <td style="width: auto; vertical-align: top;">
            <div style="color: #1F1F1F;">take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned,
              it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in
              such attorney-in-fact's discretion.</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <div style="text-indent: 36pt; color: #1F1F1F;">The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of
      any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such
      attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing
      attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the Securities Exchange Act of 1934.</div>
    <div><br>
    </div>
    <div style="text-indent: 36pt;"><font style="color: #1F1F1F;">This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4, and 5 with respect to the undersigned's holdings of and
        transactions in securities issued by the Company, unless earlier (a) revoked by the undersigned </font><font style="color: #3F3F3F;">i</font><font style="color: #1F1F1F;">n a signed writing delivered to the foregoing attorneys-in-fact or (b)
        superseded by a new power of attorney regarding the purposes outlined herein at a later date.</font></div>
    <div><br>
    </div>
    <div style="text-indent: 36pt;"><font style="color: #1F1F1F;">IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 25th</font> <font style="color: #1F1F1F;">day of October</font>,<font style="color: #1F1F1F;">
        2021.</font></div>
    <div><br>
    </div>
    <div><br>
    </div>
    <div>
      <table id="z9cebf112d4bc4d42bbf2bb8f55398240" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 25%; padding-bottom: 2px;">
              <div>&#160;</div>
            </td>
            <td style="width: 25%; padding-bottom: 2px;">
              <div>&#160;</div>
            </td>
            <td style="width: 25%; text-align: center; border-bottom: 2px solid rgb(0, 0, 0);"><font style="font-family: 'Times New Roman',Times,serif; color: rgb(31, 31, 31);">/s/ </font>Claus A. Andersson</td>
            <td style="width: 25%; padding-bottom: 2px;">
              <div>&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 25.00%;">
              <div>&#160;</div>
            </td>
            <td style="width: 25.00%;">
              <div>&#160;</div>
            </td>
            <td style="width: 25%; text-align: center;">Signature</td>
            <td style="width: 25.00%;">
              <div>&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 25.00%;">
              <div>&#160;</div>
            </td>
            <td style="width: 25.00%;">
              <div>&#160;</div>
            </td>
            <td style="width: 25.00%;">
              <div>&#160;</div>
            </td>
            <td style="width: 25.00%;">
              <div>&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 25.00%;">
              <div>&#160;</div>
            </td>
            <td style="width: 25.00%;">
              <div>&#160;</div>
            </td>
            <td style="width: 25.00%;">
              <div>&#160;</div>
            </td>
            <td style="width: 25.00%;">
              <div>&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 25.00%;">
              <div>&#160;</div>
            </td>
            <td style="width: 25.00%;">
              <div>&#160;</div>
            </td>
            <td style="width: 25.00%;">
              <div>&#160;</div>
            </td>
            <td style="width: 25.00%;">
              <div>&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 25%; padding-bottom: 2px;">
              <div>&#160;</div>
            </td>
            <td style="width: 25%; padding-bottom: 2px;">
              <div>&#160;</div>
            </td>
            <td style="width: 25%; text-align: center; border-bottom: 2px solid rgb(0, 0, 0);">Claus A. Andersson</td>
            <td style="width: 25%; padding-bottom: 2px;">
              <div>&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 25.00%;">
              <div>&#160;</div>
            </td>
            <td style="width: 25.00%;">
              <div>&#160;</div>
            </td>
            <td style="width: 25%; text-align: center;">Print Name</td>
            <td style="width: 25.00%;">
              <div>&#160;</div>
            </td>
          </tr>

      </table>
    </div>
    <div><br>
      <font style="display: inline-block; font-size: 1px; width: 180pt;" id="TRGRRTFtoHTMLTab">&#160;</font></div>
    <div style="color: rgb(31, 31, 31); font-family: 'Times New Roman',Times,serif;"><br>
    </div>
    <div><br>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
